Suppr超能文献

分析 MCP 的中性多糖部分及其对半乳糖凝集素-3 的抑制活性。

Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3.

机构信息

School of Life Sciences, Northeast Normal University, 5268 Renmin Street, Changchun, 130024, People's Republic of China.

出版信息

Glycoconj J. 2012 May;29(4):159-65. doi: 10.1007/s10719-012-9382-5. Epub 2012 May 7.

Abstract

The pH-modified citrus pectin (MCP) has been demonstrated to inhibit galectin-3 in cancer progression. The components and structures of MCP related to this inhibition remained unknown. In this paper, we fractionated MCP on DEAE-cellulose column into a homogenous neutral fraction MCP-N (about 20 kDa) and a pectin mixture fraction MCP-A (wide molecular distribution on Sepharose CL-6B chromatography). Both MCP-N and MCP-A inhibited hemagglutination mediated by galectin-3 with minimum inhibition concentration (MIC) 625 and 0.5 μg/ml, respectively. MCP-N was identified to be a type I arabinogalactan (AG-I) with a main chain of β-1→4-galactan. MCP-N was digested by α-L-arabinofuranosidase to give its main chain structure fraction (M-galactan, around 18 kDa), which was more active than the original molecule, MIC 50 μg/ml. The acidic degradation of M-galactan increased the inhibitory activity, MIC about 5 times lower than M-galactan. These results above showed that the functional motif of the β-1→4-galactan fragment might lie in the terminal residues rather than in the internal region of the chain. Therefore, MCP-N and its degraded products might be developed to new potential galectin-3 inhibitors. This is the first report concerning the fractionation of MCP and its components on galectin-3 inhibition. The information provided in this paper is valuable for screening more active galectin-3 inhibitors from natural polysaccharides.

摘要

经证实,pH 修饰的柑橘果胶(MCP)可抑制癌症进展中的半乳糖凝集素-3。与这种抑制作用相关的 MCP 的成分和结构尚不清楚。在本文中,我们在 DEAE-纤维素柱上将 MCP 分为均一的中性部分 MCP-N(约 20 kDa)和果胶混合物部分 MCP-A(在 Sepharose CL-6B 层析中具有广泛的分子分布)。MCP-N 和 MCP-A 均能抑制半乳糖凝集素-3介导的血凝作用,最小抑制浓度(MIC)分别为 625 和 0.5 μg/ml。MCP-N 被鉴定为具有主链为β-1→4-半乳糖的 I 型阿拉伯半乳聚糖(AG-I)。MCP-N 被α-L-阿拉伯呋喃糖苷酶消化,得到其主链结构部分(M-半乳糖,约 18 kDa),其活性比原始分子更高,MIC 为 50 μg/ml。M-半乳糖的酸性降解增加了抑制活性,MIC 比 M-半乳糖低约 5 倍。这些结果表明,β-1→4-半乳糖片段的功能基可能位于末端残基而不是链的内部区域。因此,MCP-N 及其降解产物可能被开发为新的潜在半乳糖凝集素-3 抑制剂。这是首次报道关于 MCP 及其组分对半乳糖凝集素-3 抑制作用的分离。本文提供的信息对于从天然多糖中筛选更有效的半乳糖凝集素-3 抑制剂具有重要价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验